RGNX: Lowering target price to $49.00

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect.

Subscribe to Yahoo Finance Plus Essential for full access

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Try it Free